The chemotherapy induced nausea vomiting market was valued at USD 1.80 Billion in 2025 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.50% during the forecast period of 2026-2035 and attain a market value of USD 2.80 Billion by 2035. The rising cancer incidence is boosting the need for effective antiemetics, supporting long-term market expansion. Advancements in R&D and personalized medicine are driving innovation in targeted and combination chemotherapy induced nausea and vomiting treatments.
Base Year
Historical Period
Forecast Period
Advancements in antiemetic drug formulations are improving patient adherence and driving consistent market growth across oncology centers.
Increased chemotherapy usage globally is directly fueling demand for supportive CINV treatments to improve patient comfort and outcomes.
Expanding awareness and guidelines for preventive CINV therapy are supporting wider adoption in both high- and middle-income countries.
Compound Annual Growth Rate
4.5%
Value in USD Billion
2026-2035
*this image is indicative*
Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, caused by the body’s reaction to chemotherapy drugs. It can occur during or after treatment and may be acute, delayed, or anticipatory. CINV significantly affects patients' quality of life and treatment adherence, making the use of antiemetic medications essential for effective symptom management and patient comfort. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2026-2035.
Adoption of Ready-to-use Injectables to Drive Market Growth
Growing demand for convenient, safe, and efficient antiemetic delivery, along with a rising focus on pediatric and high-risk cancer patients, is shaping the evolution of the market. For instance, in July 2024, Amneal Pharmaceuticals and Steriscience launched a novel ready-to-use injectable formulation of fosaprepitant, free from Polysorbate 80 and requiring no reconstitution. This single-dose vial, FOCINVEZ, supports adult and pediatric CINV prevention in highly and moderately emetogenic chemotherapy. The innovation enhances hospital and clinic workflow efficiency while improving patient safety and adherence. This launch is expected to significantly contribute to market growth during the forecast period by offering differentiated, patient-centric antiemetic solutions that align with ongoing demand for ready-to-administer therapies.
Major market trends include rising clinical innovations, preference for combination therapies, and an emphasis on providing solutions for children among others.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Therapy
Market Breakup by Population Type
Market Breakup by Drug Type
Market Breakup by Route of Administration
- Market Breakup by End User
- Market Breakup by Distribution Channel
- Market Breakup by Region
Serotonin Receptor Antagonists to Lead the Market Share by Therapy
Serotonin receptor antagonists are expected to hold a substantial share due to their widespread use and proven efficacy. NK-1 receptor antagonists follow, offering enhanced control in combination therapies. The others category, including corticosteroids and novel agents, holds a smaller share but contributes to comprehensive treatment approaches, especially in patients with refractory symptoms or complex chemotherapy regimens.
The United States is likely to hold the largest market share, driven by high chemotherapy adoption rates and access to advanced antiemetic therapies. Japan follows closely due to its ageing population and strong oncology care infrastructure. European countries Germany, France, Italy, Spain, and the UK, exhibit moderate growth with standardized treatment guidelines. India shows emerging potential, though limited access and affordability constraints currently restrict its overall market contribution.
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy’s Laboratories is a global pharmaceutical company with a strong presence in generics, active pharmaceutical ingredients, and biosimilars. In the chemotherapy-induced nausea and vomiting (CINV) market, it offers antiemetic formulations like Ondansetron and Palonosetron, supporting cancer care through affordable, high-quality medicines distributed across regulated and emerging markets.
Established in 2004 and headquartered in Surat, India, CTX Lifesciences is known for manufacturing APIs and intermediates, particularly for oncology and antiemetic segments. In the CINV market, the company provides active pharmaceutical ingredients like Ondansetron and Granisetron to global formulation companies, supporting cost-effective antiemetic drug production across various international regulatory frameworks.
Headquartered in New York, USA, and founded in 1849, Pfizer is one of the world's largest biopharmaceutical companies. In the chemotherapy-induced nausea and vomiting (CINV) segment, Pfizer markets leading antiemetic products like Emend (Aprepitant), an NK1 receptor antagonist. Its innovative oncology support therapies are widely used in hospitals and oncology clinics globally.
Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals operates internationally with a strong generics and specialty drug portfolio. In the chemotherapy induced nausea vomiting market, it offers generic formulations such as Ondansetron and Palonosetron. Glenmark supports global cancer treatment protocols by delivering accessible and effective antiemetic drugs to healthcare systems across developed and developing regions.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Gmt Pharma, Mountainside Medical, Cipla Limited, GlaxoSmithKline plc, Merck and Co. Inc., and Novartis AG.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by Population Type |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share